In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how ...